Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized molecular-driven surgery according to BRCA mutational status in advanced epithelial ovarian cancer with high tumor load
2019-002474-30Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of olaparib in epithelial ovarian cancer (EOC) and Serous Papillary Cystadenocarcinoma, sponsored by Policlinico Gemelli. Primary endpoint: Progression-free survival. Started Jun 2021; status: terminated.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on 2019-002474-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002474-30.